Pamela Layton was most recently the President and a member of the Board of Bioarray Genetics (www.bioarray.us), a molecular diagnostics company focused on the development of predictive tests, that eliminate the "one size fits all" approach to cancer treatment. The companies lead tests include a predictive test for triple negative breast cancer and a blood biopsy focused on the recurrence of multiple cancer types. Mrs. Layton’s role at the company spanned the acquisition of capital, operations, reimbursement, regulatory path and partnerships.
Prior to Bioarray, Mrs. Layton was the founder and CEO of Parcell Laboratories and was responsible for taking the first pure stem cell product from bench to bedside for spinal fusion surgeries. She holds multiple U.S. and European patents for the ELA cell and its applications. Prior to founding Parcell, she was the founder and President of TriGuard Group LLC, a security information company that partnered with a subsidiary of ADT to bring a novel alarm notification platform to the market. Mrs. Layton holds the patent for the TriGuard Information Platform. Prior to TriGuard, she spent seven years providing creative financing structures to domestic and international companies in her capacity at Bankers Trust, Chemical Bank and Boston Company Real Estate Counsel.
Mrs. Layton is a Certified Tissue Bank Specialist as designated by the American Association of Tissue Banks (AATB). In addition to mentoring young companies throughout the U.S., she is a member of the Board of Pioneer Institute, the Board of XenoTherapeutics, the Treasurer of the Board of Mother Brook Arts Center, and a long-standing judge for the New England Business Association Innovation Awards. Mrs. Layton is a member of Launchpad and Sky Ventures, as well as an individual angel investor.